Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
The 21-year-old defender from Palazzolo will undergo a CT scan to establish the diagnosis and recovery times and evaluate the possibility of surgery ...
Results that may be inaccessible to you are currently showing.